Boston, MA – According to filings with the U.S. Securities and Exchange Commission, Beacon Biosignals is raising $29,850,019.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Jacob Donoghue played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Beacon Biosignals
Beacons AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain. Beacons EEG neurobiomarker platform is engineered to accelerate clinical trials and enable new treatments for patients with neurological and psychiatric disease. We partner with biopharma companies, academic medical centers, and neurotechnology developers to improve the diagnosis and treatment of neurological and psychiatric diseases.

To learn more about Beacon Biosignals, visit http://beacon.bio/

Contact:
Jacob Donoghue, President and Chief Executive Officer
401-225-5782
jacob@beacon.bio
https://www.linkedin.com/in/jacob-donoghue-mdphd/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved